member
intern
pediatr
lung
transplant
collabor
invit
particip
multicent
retrospect
cohort
studi
fourteen
invit
center
contribut
data
studi
particip
center
obtain
approv
respect
institut
review
board
unit
state
center
ethic
committe
european
center
princip
investig
perform
comprehens
retrospect
chart
review
patient
underw
primari
lung
transplant
januari
time
data
collect
rang
august
medic
chart
review
includ
clinic
record
discharg
summari
visit
note
correspond
letter
biopsi
report
microbiolog
test
result
pulmonari
function
test
measur
diagnost
imag
year
post
transplant
death
retransplant
either
event
occur
year
post
transplant
inform
gather
includ
demograph
inform
induct
initi
immunosuppress
therapeut
regimen
prophylaxi
regimen
lymphoprolif
disord
ptld
acut
reject
episod
bobo
viral
fungal
infect
applic
date
caus
death
patient
identifi
remov
data
time
medic
chart
review
evalu
patient
perform
accord
standard
protocol
particip
institut
use
induct
immunosuppress
therapi
vari
studi
period
across
particip
center
rang
therapi
receipt
lympholyt
agent
receptor
antagonist
transplant
patient
receiv
immunosuppress
calcineurin
inhibitor
cni
prednison
either
azathioprin
mycophenol
mofetil
patient
gradual
reduct
immunosuppress
therapi
time
transplant
increas
evid
signific
acut
chronic
graft
reject
radiograph
transbronchi
biopsi
lung
function
test
result
target
cni
trough
serum
concentr
vari
center
record
studi
addit
prophylaxi
cytomegaloviru
cmv
routin
transbronchi
biopsi
assess
reject
standard
across
center
chang
time
within
center
prophylaxi
rvi
routin
prescrib
institut
administ
amantadin
durat
studi
although
individu
subject
institut
may
receiv
prevent
therapi
vaccin
influenza
routin
recommend
particip
site
although
subject
may
receiv
vaccin
first
year
transplant
due
time
transplant
diagnosi
base
upon
posit
viral
identif
bronchoalveolar
lavag
bal
bronchial
wash
tracheal
aspir
sputum
nasopharyng
swab
specimen
addit
clinic
evid
infect
clinic
evid
viral
infect
indic
rhinorrhea
cough
fever
support
suggest
radiograph
andor
transbronchi
biopsi
find
site
rvi
specimen
record
avail
medic
chart
although
distinct
made
upper
lower
rvi
due
limit
data
avail
direct
fluoresc
antibodi
test
viral
cultur
polymeras
chain
reaction
pcr
princip
diagnost
method
use
applic
specif
methodolog
assay
vari
within
institut
episod
clinic
evid
viral
infect
without
identif
specif
viral
etiolog
exclud
studi
episod
infect
base
upon
laboratori
document
use
diagnosi
grade
perform
individu
center
without
review
central
patholog
core
grade
base
upon
identif
perivascular
lymphocyt
infiltr
transbronchi
biopsi
specimen
use
defin
classif
scheme
pulmonari
allograft
reject
addit
clinic
suspicion
acut
reject
result
enhanc
immunosuppress
intraven
methylprednison
agent
without
definit
patholog
evid
note
diagnosi
grade
bo
base
histolog
identif
fibrou
scar
small
conduct
airway
partial
complet
obliter
airway
lumen
transbronchi
biopsi
specimen
defin
intern
societi
heart
lung
transplant
diagnosi
bo
base
chang
pulmonari
function
test
result
avail
clinic
chart
particularli
measur
use
criteria
reflect
current
standard
intern
societi
heart
lung
transplant
patient
inform
compil
enter
oracl
databas
data
analys
perform
use
sa
version
sa
institut
cari
north
carolina
usa
graphic
produc
use
r
version
softwar
r
foundat
statist
comput
vienna
austria
comparison
demograph
data
outcom
infect
uninfect
cohort
perform
use
wilcoxon
test
continu
variabl
test
fisher
exact
test
categor
variabl
appropri
associ
demograph
clinic
factor
morbid
includ
first
second
episod
acut
reject
chronic
reject
episod
ptld
first
cmv
infect
pulmonari
fungal
infect
time
rvi
rvi
time
morbid
mortal
assess
use
cox
proport
hazard
model
censor
death
retranspl
year
post
transplant
use
risk
factor
model
rvi
morbid
model
covari
test
perform
signific
level
subject
studi
subject
develop
episod
rvi
within
first
year
transplant
singl
document
episod
rvi
common
howev
develop
rvi
subject
episod
mean
number
rvi
per
infect
subject
specimen
retriev
nasopharyng
swab
trachea
bal
specimen
sourc
document
methodolog
viral
discoveri
record
episod
viral
cultur
predomin
addit
posit
result
obtain
direct
fluoresc
antibodi
test
pcr
rvi
occur
earli
cours
mean
time
first
episod
rvi
month
rang
median
time
first
rvi
episod
month
subject
durat
initi
hospit
avail
subject
episod
rvi
subject
subject
develop
episod
rvi
initi
hospit
nosocomi
rate
subset
subject
rvi
initi
hospit
hospit
median
day
compar
day
day
without
rvi
first
hospit
respect
addit
subject
rvi
first
hospit
die
retranspl
within
year
compar
without
rvi
rvi
first
hospit
subject
rvi
first
hospit
increas
risk
death
retransplant
within
year
compar
subject
well
subject
rvi
initi
hospit
hazard
ratio
hr
confid
interv
ci
p
hr
ci
p
respect
rvi
episod
frequent
encount
viral
pathogen
adenoviru
rhinoviru
rsv
parainfluenza
virus
remain
pathogen
includ
herp
simplex
viru
hsv
enterovirus
influenza
ab
tabl
distribut
viral
infect
vari
depend
age
subject
subject
year
age
develop
rvi
episod
organ
recov
includ
adenoviru
episod
parainfluenza
rsv
rhinoviru
enteroviru
influenza
subject
older
year
subject
record
least
rvi
episod
group
rhinoviru
episod
rsv
occur
frequent
adenoviru
parainfluenza
influenza
enteroviru
season
distribut
rvi
observ
virus
fig
virus
commonli
recov
winter
month
influenza
rsv
adenoviru
occur
frequent
spring
month
parainfluenza
rhinoviru
peak
fall
spring
herpesviru
infect
occur
rare
hsv
present
pneumon
document
episod
singl
subject
varicella
die
secondari
dissemin
varicella
zoster
viru
infect
associ
pneumon
sever
featur
distinguish
subject
rvi
within
first
year
post
transplant
uninfect
cohort
tabl
specif
subject
rvi
like
younger
age
rvi
year
without
rvi
year
p
underli
diagnosi
cf
p
subject
receiv
live
donor
bilater
cadaver
transplant
highest
proport
rvi
compar
singl
lung
transplant
recipi
signific
differ
subject
without
rvi
observ
distribut
transplant
type
p
howev
small
sampl
size
group
limit
abil
perform
comparison
addit
age
transplant
factor
univari
associ
time
rvi
includ
induct
therapi
regimen
tabl
younger
age
transplant
associ
increas
risk
rvi
youngest
transplant
recipi
year
age
greatest
risk
hr
ci
increas
risk
rvi
diminish
age
transplant
reach
year
subject
receiv
induct
therapi
underli
etiolog
cf
treat
cyclosporin
versu
tacrolimu
increas
risk
rvi
p
respect
significantli
increas
risk
rvi
seen
prior
episod
cmv
acut
reject
multipl
episod
treat
reject
bo
multivari
cox
proport
hazard
model
tabl
age
year
time
transplant
underli
etiolog
cf
remain
signific
risk
factor
develop
rvi
age
hr
ci
hr
ci
p
subject
cf
like
older
interact
factor
statist
signific
second
multivari
model
receipt
induct
therapi
found
protect
rvi
hr
ci
age
younger
year
etiolog
cf
remain
signific
risk
prior
episod
cmv
episod
acut
reject
immunosuppress
includ
use
cyclosporin
significantli
associ
subsequ
rvi
multivari
model
episod
preced
rvi
significantli
associ
develop
subsequ
morbid
within
first
year
includ
acut
reject
episod
treat
cmv
infect
diseas
develop
bo
p
morbid
data
shown
rvi
risk
factor
death
retransplant
within
first
year
pediatr
lung
transplant
rvi
remain
predictor
death
retransplant
within
first
year
transplant
univari
analysi
hr
ci
p
remain
predict
previous
report
risk
death
popul
ad
model
includ
pulmonari
fungal
infect
bo
within
year
transplant
tabl
site
viral
recoveri
associ
mortal
retransplant
viru
recov
bal
die
receiv
second
transplant
compar
surviv
year
post
transplant
pediatr
popul
lung
transplant
accept
treatment
varieti
pulmonari
diseas
howev
despit
advanc
surgic
care
manag
pediatr
mortal
rate
post
lung
transplant
remain
rel
unchang
among
highest
rate
pediatr
solid
organ
transplant
procedur
rvi
repres
potenti
obstacl
achiev
improv
outcom
previou
studi
demonstr
rvi
occur
mani
adult
lung
transplant
recipi
associ
morbid
includ
bo
small
cohort
pediatr
subject
adenoviru
infect
associ
graft
failur
death
howev
current
scientif
literatur
lack
comprehens
examin
risk
factor
impact
rvi
pediatr
lung
transplant
retrospect
studi
evalu
incid
impact
rvi
pediatr
lung
transplant
recipi
multipl
center
throughout
unit
state
europ
compar
previou
report
rvi
adult
lung
transplant
recipi
rang
rvi
occur
pediatr
subject
cohort
season
variat
virus
encount
reflect
seen
gener
pediatr
popul
clinician
awar
circul
commun
acquir
viral
infect
assist
prepar
patient
hospit
discharg
also
evalu
patient
return
acut
ill
addit
virus
recov
similar
report
previou
studi
rhinoviru
recent
recov
convent
viral
cultur
compris
signific
proport
rvi
similar
report
adult
reflect
import
test
method
newli
avail
molecular
test
becom
wide
avail
respiratori
specimen
detect
rhinoviru
also
emerg
virus
coronaviru
human
metapneumoviru
risk
factor
rvi
previous
evalu
lung
transplant
cohort
younger
age
time
transplant
absenc
induct
therapi
etiolog
cf
immunosuppress
regimen
identifi
independ
risk
factor
develop
rvi
within
first
year
follow
lung
transplant
younger
age
etiolog
transplant
independ
signific
risk
factor
without
evid
interact
younger
children
may
increas
risk
rvi
sever
reason
includ
immunolog
naiveti
increas
exposur
infecti
peer
seen
gener
popul
addit
proport
subject
adenoviru
year
age
significantli
higher
older
cohort
although
studi
distinguish
primari
adenovir
infect
reactiv
latent
viru
younger
children
shown
harbor
viru
higher
level
tonsil
reactiv
vitro
stimul
provid
anoth
potenti
mechan
increas
risk
rvi
young
transplant
recipi
observ
young
age
associ
rvi
develop
contrast
observ
pulmonari
fungal
infect
pediatr
lung
transplant
recipi
older
age
independ
risk
factor
suggest
patient
may
risk
distinctli
differ
infect
base
age
transplant
lack
induct
therapi
independ
risk
factor
rvi
appear
counterintuit
subject
may
expect
less
immunosuppress
earli
period
lack
induct
therapi
associ
increas
episod
acut
reject
includ
enhanc
immunosuppress
intraven
steroid
could
increas
rel
immunosuppress
state
group
theoret
increas
risk
rvi
interestingli
acut
reject
episod
associ
increas
risk
rvi
studi
requir
elucid
mechan
induct
therapi
could
reduc
individu
suscept
rvi
although
preced
rvi
significantli
associ
morbid
bo
studi
may
product
inher
limit
assess
outcom
year
transplant
bo
develop
subject
within
first
year
transplant
extend
evalu
associ
rvi
bo
perform
futur
popul
assess
relationship
report
adult
popul
howev
rvi
especi
rvi
within
hospit
transplant
found
risk
factor
mortal
retransplant
within
first
year
follow
pediatr
lung
transplant
retrospect
studi
limit
relat
studi
design
avail
data
select
bia
addit
particip
institut
util
independ
protocol
evalu
induct
immunosuppress
therapi
surveil
diagnosi
reject
infect
use
induct
immunosuppress
therapi
also
vari
studi
period
minim
effect
tempor
differ
data
collect
perform
princip
investig
particip
site
strict
adher
specif
predetermin
definit
second
limit
studi
involv
rvi
diagnosi
diagnost
test
particip
center
routin
evalu
rvi
episod
cold
symptom
potenti
underestim
number
episod
rvi
addit
mention
previous
test
method
vari
across
within
center
studi
period
includ
recent
era
molecular
diagnost
allow
increas
sensit
identif
rvi
respiratori
viral
specimen
includ
previous
unidentifi
virus
like
human
metapneumoviru
prospect
studi
intercurr
cold
symptom
use
molecular
diagnost
detect
vast
number
respiratori
virus
includ
newli
discov
human
metapneumoviru
coronavirus
bocavirus
improv
understand
rvi
potenti
impact
pediatr
lung
transplant
lack
differenti
upper
lower
rvi
anoth
limit
type
infect
agent
importantli
impact
significantli
differ
class
rvi
rvi
lower
tract
report
carri
seriou
risk
subsequ
mortal
reject
post
transplant
unfortun
locat
rvi
could
account
studi
owe
limit
avail
inform
specif
site
specimen
collect
viral
cultur
diagnosi
addit
exclus
clinic
episod
along
lack
routin
screen
protocol
rvi
period
data
collect
like
underestim
actual
incid
rvi
popul
underestim
rvi
especi
sever
episod
detect
may
overestim
impact
rvi
popul
prospect
collect
cohort
includ
molecular
evalu
symptomat
episod
process
durat
viral
shed
address
studi
howev
report
literatur
indic
viral
shed
rhinoviru
rsv
may
prolong
transplant
recipi
clinician
consid
possibl
continu
recurr
symptom
rvi
although
nosocomi
rvi
specif
delin
data
collect
signific
number
earli
nosocomi
infect
detect
analysi
larg
subset
subject
durat
transplant
hospit
known
increas
awar
enhanc
infect
control
measur
could
decreas
risk
earli
rvi
popul
limit
examin
outcom
year
transplant
also
requir
comment
although
infect
seriou
complic
beyond
month
year
post
transplant
remain
potenti
seriou
complic
regardless
time
sinc
transplant
limit
analysi
outcom
year
post
transplant
may
censor
true
occurr
rvi
patient
popul
furthermor
possibl
relationship
report
rvi
pretranspl
risk
factor
neg
outcom
chronic
graft
reject
andor
retransplant
may
manifest
within
first
year
post
transplant
limit
abil
identifi
signific
associ
case
hr
univari
multivari
cox
proport
model
may
artifici
low
moreov
truli
signific
risk
factor
event
may
exclud
altogeth
addit
impact
newer
rvi
therapeut
cidofovir
adenoviru
ribavirin
rsv
human
metapneumoviru
may
impact
outcom
relat
treat
rvi
futur
studi
plan
examin
associ
rvi
morbid
acut
chronic
graft
reject
beyond
year
post
transplant
studi
provid
first
evalu
rvi
pediatr
lung
transplant
popul
across
wide
rang
pediatr
transplant
program
unit
state
europ
despit
inher
limit
studi
design
data
indic
younger
age
etiolog
transplant
cf
independ
risk
factor
develop
rvi
within
first
year
pediatr
lung
transplant
addit
singl
episod
rvi
associ
death
retransplant
year
post
transplant
even
control
known
mortal
risk
futur
studi
must
prospect
evalu
incid
rvi
popul
differenti
upper
tract
lower
tract
rvi
follow
associ
rvi
later
outcom
beyond
year
post
transplant
